RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...

Moderna has outlicensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

Moderna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia.

Italian pharma major Recordati has entered into a collaboration and license agreement with US mRNA specialist Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for ...

Cholesterol bloodstream The FDA has granted Fast Track designation to mRNA-3927 (Moderna), an investigational mRNA therapeutic for propionic acidemia. The Food and Drug Administration (FDA) has ...

mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic acidemia) “Fast Track designation underscores the urgent need for a ...

Propionic acidemia is caused by mutations in an enzyme called propionyl-CoA carboxylase. CoA is a helper molecule essential for energy metabolism. Propionic acidemia is typically managed by diet. The ...

The Food and Drug Administration (FDA) has approved a new indication for Carbaglu ® (carglumic acid; Recordati Rare Diseases) for use as adjunctive therapy in the treatment of acute hyperammonemia due ...

Metabolic disorders and organic acidemias comprise a diverse group of inherited conditions in which enzymatic deficiencies disrupt normal metabolic pathways. Such deficiencies lead to the accumulation ...

Creating awareness for a little known disease — propionic acidemia — was important to students who raised money during the annual Deerfield High School School Chest drive this year because the cause ...